Soo RA, Han JY, Dafni U, Cho BC, et al. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER tria Ann Oncol 2022;33:181-192.
PMID: 34839016